VELRAYDY
Live / Allowed — Notice of allowance issued (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99303003
- Mark type
- Stylized text
- Filed
- 25 Jul 2025
- Published for opposition
- 13 Jan 2026
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 10 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Jan 2026 — PUBLISHED FOR OPPOSITION
- 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Dec 2025 — ASSIGNED TO EXAMINER
- 20 Aug 2025 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
- 18 Aug 2025 — ASSIGNED TO LIE
- 06 Aug 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 25 Jul 2025 — APPLICATION FILING RECEIPT MAILED
- 25 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 25 Jul 2025 — NEW APPLICATION ENTERED